Nuveen Asset Management LLC lowered its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,252 shares of the company’s stock after selling 878 shares during the period. Nuveen Asset Management LLC’s holdings in Myriad Genetics were worth $312,000 as of its most recent filing with the SEC.
Several other hedge funds have also modified their holdings of MYGN. Piedmont Investment Advisors LLC increased its stake in shares of Myriad Genetics by 131.7% in the first quarter. Piedmont Investment Advisors LLC now owns 84,513 shares of the company’s stock worth $1,623,000 after buying an additional 48,036 shares during the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Myriad Genetics by 1.2% in the first quarter. Public Employees Retirement System of Ohio now owns 141,556 shares of the company’s stock worth $2,718,000 after buying an additional 1,648 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Myriad Genetics during the first quarter worth about $453,000. Gotham Asset Management LLC boosted its position in shares of Myriad Genetics by 20.8% in the first quarter. Gotham Asset Management LLC now owns 349,262 shares of the company’s stock worth $6,706,000 after buying an additional 60,220 shares during the period. Finally, Highbridge Capital Management LLC boosted its position in shares of Myriad Genetics by 29.5% in the first quarter. Highbridge Capital Management LLC now owns 36,513 shares of the company’s stock worth $701,000 after buying an additional 8,317 shares during the period.
Myriad Genetics, Inc. (NASDAQ:MYGN) traded down 1.65% on Wednesday, hitting $23.82. The stock had a trading volume of 218,085 shares. The company’s 50 day moving average price is $24.85 and its 200-day moving average price is $20.44. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 50.90 and a beta of 0.31. Myriad Genetics, Inc. has a 12-month low of $15.15 and a 12-month high of $32.05. Myriad Genetics also was the recipient of some unusual options trading on Monday. Traders bought 9,337 put options on the stock. This represents an increase of 1,917% compared to the typical daily volume of 463 put options.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The firm had revenue of $196.90 million for the quarter, compared to analysts’ expectations of $188.89 million. Equities research analysts anticipate that Myriad Genetics, Inc. will post $1.01 EPS for the current year.
A number of equities analysts recently commented on MYGN shares. J P Morgan Chase & Co restated an “underweight” rating and set a $16.00 target price on shares of Myriad Genetics in a report on Friday, June 30th. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Jefferies Group LLC restated a “hold” rating and set a $21.00 target price (up from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Deutsche Bank AG raised their target price on Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Finally, Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a report on Monday, July 17th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. Myriad Genetics presently has an average rating of “Hold” and a consensus target price of $21.77.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
